Date icon

Apr 1, 2022 | 14:00 GMT

  • istesso
    Lisa Patel Istesso, CEO
Is This IPG's Next Unicorn?

IP Group believe portfolio company, Istesso, could potentially be its next unicorn.

Istesso is an immunometabolism drug discovery and development company with an extremely promising rheumatoid arthritis drug currently in Phase II trials.

Rheumatoid arthritis is a painful, chronic autoimmune disease that affects as many as 1 in 200 people, 30% of whom do not respond to current medications.

We’re excited to be joined by IP Group’s Life Sciences Managing Partner, Dr Sam Williams, also Co-founder and Chairman of Istesso, who will outline why the company holds so much potential.


  • Health
  • Companies
  • Educational
  • Micro cap
  • UK